-
Je něco špatně v tomto záznamu ?
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines
GK. Bonney, CA. Chew, P. Lodge, J. Hubbard, KJ. Halazun, P. Trunecka, P. Muiesan, DF. Mirza, J. Isaac, RW. Laing, SG. Iyer, CE. Chee, WP. Yong, MD. Muthiah, F. Panaro, J. Sanabria, A. Grothey, K. Moodley, I. Chau, ACY. Chan, CC. Wang, K. Menon,...
Jazyk angličtina Země Nizozemsko
Typ dokumentu konsensus - konference, časopisecké články, směrnice pro lékařskou praxi
- MeSH
- adenokarcinom diagnóza sekundární chirurgie MeSH
- delfská metoda MeSH
- klinické rozhodování metody MeSH
- kolorektální nádory patologie MeSH
- lidé MeSH
- nádory jater diagnóza sekundární chirurgie MeSH
- prognóza MeSH
- transplantace jater metody normy MeSH
- výběr pacientů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- směrnice pro lékařskou praxi MeSH
Colorectal cancer is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Despite advances in improving resectability, most patients present with non-resectable colorectal liver metastases requiring palliative systemic therapy and locoregional disease control strategies. There is a growing interest in the use of liver transplantation to treat non-resectable colorectal liver metastases in well selected patients, leading to a surge in the number of studies and prospective trials worldwide, thereby fuelling the emerging field of transplant oncology. The interdisciplinary nature of this field requires domain-specific evidence and expertise to be drawn from multiple clinical specialities and the basic sciences. Importantly, the wider societal implication of liver transplantation for non-resectable colorectal liver metastases, such as the effect on the allocation of resources and national transplant waitlists, should be considered. To address the urgent need for a consensus approach, the International Hepato-Pancreato-Biliary Association commissioned the Liver Transplantation for Colorectal liver Metastases 2021 working group, consisting of international leaders in the areas of hepatobiliary surgery, colorectal oncology, liver transplantation, hepatology, and bioethics. The aim of this study was to standardise nomenclature and define management principles in five key domains: patient selection, evaluation of biological behaviour, graft selection, recipient considerations, and outcomes. An extensive literature review was done within the five domains identified. Between November, 2020, and January, 2021, a three-step modified Delphi consensus process was undertaken by the workgroup, who were further subgrouped into the Scientific Committee, Expert Panel, and Transplant Centre Representatives. A final consensus of 44 statements, standardised nomenclature, and a practical management algorithm is presented. Specific criteria for clinico-patho-radiological assessments with molecular profiling is crucial in this setting. After this, the careful evaluation of biological behaviour with bridging therapy to transplantation with an appropriate assessment of the response is required. The sequencing of treatment in synchronous metastatic disease requires special consideration and is highlighted here. Some ethical dilemmas within organ allocation for malignant indications are discussed and the role for extended criteria grafts, living donor transplantation, and machine perfusion technologies for non-resectable colorectal liver metastases are reviewed. Appropriate immunosuppressive regimens and strategies for the follow-up and treatment of recurrent disease are proposed. This consensus guideline provides a framework by which liver transplantation for non-resectable colorectal liver metastases might be safely instituted and is a meaningful step towards future evidenced-based practice for better patient selection and organ allocation to improve the survival for patients with this disease.
Department of Haematology Oncology National University Cancer Institute Singapore
Department of Hepatobiliary Surgery Careggi University Hospital Florence Italy
Department of Medical Oncology Mayo Clinic Rochester MN USA
Department of Medical Oncology West Cancer Center and Research Institute Germantown TN USA
Department of Medicine Royal Marsden Hospital London UK
Department of Surgery Case Western Reserve University School of Medicine Cleveland OH USA
Department of Transplantation and Hepatobiliary Surgery Leeds Teaching Hospital NHS Trust Leeds UK
Department of Transplantation Medicine Oslo University Hospital Oslo Norway
Division of Gastroenterology and Hepatology National University Hospital Singapore
Division of Hepatobiliary and Pancreatic Surgery National University Hospital Singapore
Division of Liver Transplantation Hepatobiliary and Pancreatic Surgery Queen Mary Hospital Hong Kong
Institute of Clinical Medicine University of Oslo Oslo Norway
Institute of Liver Studies King's College Hospital London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003339
- 003
- CZ-PrNML
- 005
- 20220127150326.0
- 007
- ta
- 008
- 220113s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2468-1253(21)00219-3 $2 doi
- 035 __
- $a (PubMed)34506756
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bonney, Glenn K $u Division of Hepatobiliary and Pancreatic Surgery, National University Hospital, Singapore. Electronic address: glenn_bonney@nuhs.edu.sg
- 245 10
- $a Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines / $c GK. Bonney, CA. Chew, P. Lodge, J. Hubbard, KJ. Halazun, P. Trunecka, P. Muiesan, DF. Mirza, J. Isaac, RW. Laing, SG. Iyer, CE. Chee, WP. Yong, MD. Muthiah, F. Panaro, J. Sanabria, A. Grothey, K. Moodley, I. Chau, ACY. Chan, CC. Wang, K. Menon, G. Sapisochin, M. Hagness, S. Dueland, PD. Line, R. Adam
- 520 9_
- $a Colorectal cancer is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Despite advances in improving resectability, most patients present with non-resectable colorectal liver metastases requiring palliative systemic therapy and locoregional disease control strategies. There is a growing interest in the use of liver transplantation to treat non-resectable colorectal liver metastases in well selected patients, leading to a surge in the number of studies and prospective trials worldwide, thereby fuelling the emerging field of transplant oncology. The interdisciplinary nature of this field requires domain-specific evidence and expertise to be drawn from multiple clinical specialities and the basic sciences. Importantly, the wider societal implication of liver transplantation for non-resectable colorectal liver metastases, such as the effect on the allocation of resources and national transplant waitlists, should be considered. To address the urgent need for a consensus approach, the International Hepato-Pancreato-Biliary Association commissioned the Liver Transplantation for Colorectal liver Metastases 2021 working group, consisting of international leaders in the areas of hepatobiliary surgery, colorectal oncology, liver transplantation, hepatology, and bioethics. The aim of this study was to standardise nomenclature and define management principles in five key domains: patient selection, evaluation of biological behaviour, graft selection, recipient considerations, and outcomes. An extensive literature review was done within the five domains identified. Between November, 2020, and January, 2021, a three-step modified Delphi consensus process was undertaken by the workgroup, who were further subgrouped into the Scientific Committee, Expert Panel, and Transplant Centre Representatives. A final consensus of 44 statements, standardised nomenclature, and a practical management algorithm is presented. Specific criteria for clinico-patho-radiological assessments with molecular profiling is crucial in this setting. After this, the careful evaluation of biological behaviour with bridging therapy to transplantation with an appropriate assessment of the response is required. The sequencing of treatment in synchronous metastatic disease requires special consideration and is highlighted here. Some ethical dilemmas within organ allocation for malignant indications are discussed and the role for extended criteria grafts, living donor transplantation, and machine perfusion technologies for non-resectable colorectal liver metastases are reviewed. Appropriate immunosuppressive regimens and strategies for the follow-up and treatment of recurrent disease are proposed. This consensus guideline provides a framework by which liver transplantation for non-resectable colorectal liver metastases might be safely instituted and is a meaningful step towards future evidenced-based practice for better patient selection and organ allocation to improve the survival for patients with this disease.
- 650 _2
- $a adenokarcinom $x diagnóza $x sekundární $x chirurgie $7 D000230
- 650 _2
- $a klinické rozhodování $x metody $7 D000066491
- 650 _2
- $a kolorektální nádory $x patologie $7 D015179
- 650 _2
- $a delfská metoda $7 D003697
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory jater $x diagnóza $x sekundární $x chirurgie $7 D008113
- 650 _2
- $a transplantace jater $x metody $x normy $7 D016031
- 650 _2
- $a výběr pacientů $7 D018579
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Chew, Claire Alexandra $u Division of Hepatobiliary and Pancreatic Surgery, National University Hospital, Singapore
- 700 1_
- $a Lodge, Peter $u Department of Transplantation and Hepatobiliary Surgery, Leeds Teaching Hospital NHS Trust, Leeds, UK
- 700 1_
- $a Hubbard, Joleen $u Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Halazun, Karim J $u Division of Liver Transplantation and Hepato-Pancreato-Biliary Surgery, Department of Surgery, Weill Cornell Medicine, New York City, NY, USA
- 700 1_
- $a Trunecka, Pavel $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Muiesan, Paolo $u Department of Hepatobiliary Surgery, Careggi University Hospital, Florence, Italy
- 700 1_
- $a Mirza, Darius F $u Liver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 700 1_
- $a Isaac, John $u Liver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 700 1_
- $a Laing, Richard W $u Liver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 700 1_
- $a Iyer, Shridhar Ganpathi $u Division of Hepatobiliary and Pancreatic Surgery, National University Hospital, Singapore
- 700 1_
- $a Chee, Cheng Ean $u Department of Haematology-Oncology, National University Cancer Institute, Singapore
- 700 1_
- $a Yong, Wei Peng $u Department of Haematology-Oncology, National University Cancer Institute, Singapore
- 700 1_
- $a Muthiah, Mark Dhinesh $u Division of Gastroenterology and Hepatology, National University Hospital, Singapore
- 700 1_
- $a Panaro, Fabrizio $u Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Department of Surgery, Saint Eloi Hospital, Montpellier University Hospital-School of Medicine, Montpellier, France
- 700 1_
- $a Sanabria, Juan $u Department of Surgery, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- 700 1_
- $a Grothey, Axel $u Department of Medical Oncology, West Cancer Center and Research Institute, Germantown, TN, USA
- 700 1_
- $a Moodley, Keymanthri $u The Centre of Medical Ethics and Law, Department of Medicine, Stellenbosch University, Stellenbosch, South Africa
- 700 1_
- $a Chau, Ian $u Department of Medicine, Royal Marsden Hospital, London, UK
- 700 1_
- $a Chan, Albert C Y $u Division of Liver Transplantation, Hepatobiliary & Pancreatic Surgery, Queen Mary Hospital, Hong Kong
- 700 1_
- $a Wang, Chih Chi $u Department of Surgery, Liver Transplantation Centre, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
- 700 1_
- $a Menon, Krishna $u Institute of Liver Studies, King's College Hospital, London, UK
- 700 1_
- $a Sapisochin, Gonzalo $u Abdominal Transplant and Hepato-Pancreato-Biliary Surgical Oncology, Multi-Organ Transplant Program, Division of General Surgery, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Hagness, Morten $u Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Dueland, Svein $u Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Line, Pål-Dag $u Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 700 1_
- $a Adam, René $u Hepato Biliary Surgery, Cancer and Transplantation Unit, AP-HP Paul Brousse Hospital, University Paris-Saclay, Villejuif, France
- 773 0_
- $w MED00196700 $t The lancet. Gastroenterology & hepatology $x 2468-1253 $g Roč. 6, č. 11 (2021), s. 933-946
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34506756 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127150322 $b ABA008
- 999 __
- $a ok $b bmc $g 1750955 $s 1154488
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 6 $c 11 $d 933-946 $e 20210908 $i 2468-1253 $m The lancet. Gastroenterology & hepatology $n Lancet Gastroenterol Hepatol $x MED00196700
- LZP __
- $a Pubmed-20220113
